Salud financiera de hoja de balance de Oramed Pharmaceuticals
Salud financiera controles de criterios 6/6
Oramed Pharmaceuticals has a total shareholder equity of $176.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $184.2M and $8.1M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$152.74m |
| Patrimonio | US$176.15m |
| Total pasivo | US$8.07m |
| Activos totales | US$184.22m |
Actualizaciones recientes sobre salud financiera
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06Análisis de la situación financiera
Pasivos a corto plazo: ORMP's short term assets ($153.3M) exceed its short term liabilities ($3.7M).
Pasivo a largo plazo: ORMP's short term assets ($153.3M) exceed its long term liabilities ($4.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ORMP is debt free.
Reducción de la deuda: ORMP had no debt 5 years ago.
Cobertura de la deuda: ORMP has no debt, therefore it does not need to be covered by operating cash flow.
Cobertura de intereses: ORMP has no debt, therefore coverage of interest payments is not a concern.